Oxford BioMedica (LSE:OXB) EBIT: £-17.4 Mil (TTM As of Dec. 2025)


LSE:OXB Oxford BioMedica PLC LSE:OXB
68 GF Score
Price £6.14
GF Value £5.36
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oxford BioMedica EBIT?

Oxford BioMedica LSE:OXB +2.33% 68 EBIT is £-17.4 Mil as of Dec. 2025. GuruFocus rates LSE:OXB with a GF Score™ of 68/100 and a GF Value™ of £5.36 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Oxford BioMedica's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was £1.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was £-17.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Oxford BioMedica's annualized ROC % for the quarter that ended in Dec. 2025 was -6.60%. Oxford BioMedica's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 4.20%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Oxford BioMedica's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -2.19%.


Oxford BioMedica  (LSE:OXB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Oxford BioMedica's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-18.772 * ( 1 - 36.2% )/( (150.658 + 212.444)/ 2 )
=-11.976536/181.551
=-6.60 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Oxford BioMedica's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=3.422/( ( (55.326 + max(-7.565, 0)) + (107.628 + max(-16.136, 0)) )/ 2 )
=3.422/( ( 55.326 + 107.628 )/ 2 )
=3.422/81.477
=4.20 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(26.431 + 15.595 + 15.486) - (11.782 + 0 + 53.295)
=-7.565

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(22.686 + 17.33 + 22.011) - (16.391 + 0 + 61.772)
=-16.136

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Oxford BioMedica's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-17.433/794.404
=-2.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford BioMedica EBIT Related Terms


Oxford BioMedica EBIT Historical Data

* Premium members only.

The historical data trend for Oxford BioMedica's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioMedica EBIT Chart

Oxford BioMedica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.77 -37.22 -177.33 -36.76 -17.43

Oxford BioMedica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -130.47 -30.84 -5.92 -19.14 1.71

LSE:OXB vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Oxford BioMedica's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford BioMedica EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's EV-to-EBIT falls into.


LSE:OXB
68GF Score
Oxford BioMedica PLC LSE:OXB
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oxford BioMedica EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-17.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of £-17.4 Mil mean?
Oxford BioMedica (LSE:OXB) has a EBIT of £-17.4 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Oxford BioMedica.
Is Oxford BioMedica's EBIT too high?
Oxford BioMedica's current EBIT is £-17.4 Mil. Overall, Oxford BioMedica has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's EBIT compare to VRTX and REGN?
Oxford BioMedica's EBIT of £-17.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Oxford BioMedica. Oxford BioMedica's current EBIT is £-17.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (LSE:OXB) is currently considered Modestly Overvalued. The stock's GF Value™ is £5.36, compared to a current price of £6.14 — trading 14.6% above its estimated fair value. The current EBIT is £-17.4 Mil. Oxford BioMedica's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Oxford BioMedica (LSE:OXB), the current EBIT is £-17.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oxford BioMedica (LSE:OXB) Overvalued in 2026?

Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued. The current stock price of £6.14 is trading 14.6% above its estimated GF Value™ of £5.36. GuruFocus considers Oxford BioMedica to be Modestly Overvalued.

Key valuation signals for LSE:OXB:

  • EBIT: £-17.4 Mil
  • GF Value™: £5.36 vs. price of £6.14 (14.6% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the LSE:OXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oxford BioMedica Business Description

Other Exchanges OXBDF:USAOXBl:UKOXO:Germany
Address Transport Way, Windrush Court, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
68GF Score

Get the complete analysis for LSE:OXB

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£6.14
Price
£5.36
GF Value